Type 1 Diabetes Clinical Trial
Official title:
A Randomized, Double-blind, Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Effects of Repeated Subcutaneous Doses of E1 in Combination With G1 in Type 1 Diabetes
The purpose of the study is to determine whether E1 and G1 are safe and effective in the
treatment of type 1 diabetes.
Type 1 diabetes is an autoimmune disease, in which the immune system attacks pancreatic beta
cells. These cells produce insulin, which regulates blood glucose. The mainstay of current
treatment for type 1 diabetes is dietary control and daily parenteral administration of
insulin.
Recent diabetes research has increasingly focused on pancreatic islet cell replacement,
either by islet cell transplantation or by endogenous regeneration of islet cells. During
fetal development, islet precursor cells proliferate and differentiate into mature beta cells
capable of producing insulin. This process is known as islet cell neogenesis. Islet cell
neogenesis normally ceases around birth, however, the adult pancreas still retains
significant potential for islet regeneration, as shown by tissue repair following pancreatic
injury. Pre-clinical studies have shown that E1 and G1 can re-establish islet cell neogenesis
and increase pancreatic insulin production in diabetic animal models. It is therefore
postulated that treatment with E1 and G1 may produce islet cell regeneration in type 1
diabetic patients.
In this study, 20 type 1 diabetic patients requiring insulin therapy will be randomized.
Fifteen (15) patients will be randomized to receive active study medication and 5 patients
will be randomized to receive vehicle control. After undergoing screening procedures,
potential patients will enter a 14 day baseline phase where baseline data will be collected.
Pending successful completion of the baseline phase, patient will enter a 28-day treatment
phase where they will be randomized to receive either once daily subcutaneous injections of
E1 plus G1, as separate injections or once daily subcutaneous injections of vehicle control
(as 2 separate injections). Patients will receive once daily doses in the morning after
breakfast for a period of 28 days. Upon completion of treatment, all patients will continue
in the follow-up phase for an additional 6 months and will return to the clinic for monthly
visits. Throughout the study, patients will remain on their insulin regimen and will maintain
a diary record of insulin intake and blood glucose levels.
Pancreatic beta cell function or insulin secretion is best measured by determination of
c-peptide (which is co-secreted with insulin in a 1:1 ratio). An arginine stimulated
c-peptide test will therefore be performed at frequent intervals during the study. Patients
will be injected with a solution containing arginine, a normal constituent of food that
increases insulin release from beta cells into the blood. After the injection seven blood
samples for c-peptide tests will be collected over 10 minutes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A | |
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 |